Aji Bio-Pharma Business Announcements March 29, 2021 Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines Read more January 27, 2021 Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study Read more December 22, 2020 Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection Read more November 9, 2020 Notice on email address domain changing GeneDesign, Inc. – Osaka SiteRead more October 6, 2020 First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval Read more September 29, 2020 Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic Read more August 13, 2020 Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility Read more June 30, 2020 Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing Read more June 2, 2020 Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India Read more May 27, 2020 Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19 Read more May 5, 2020 Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials Read more April 30, 2020 Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic Read more Loading…Load More
